Navigation Links
PARI Pharma's Nebulized DSCG Shows Results Similar to Inhaled Steroids in Asthma Studies Presented at ATS
Date:5/20/2009

nebulizer, such as the customized small droplet generating eFlow electronic nebulizer," stated Dr. Alexander Moeller, head of the Research Division, Respiratory Medicine at the University Children's Hospital Zurich, Switzerland.

Previous DSCG therapies were only moderately effective, since the interaction of the very hygroscopic properties of DSCG with the drug delivery system were not understood.

"We believe our novel, higher concentrated, low volume DSCG formulation delivered via an optimized Investigational eFlow Nebulizer System opens new treatment avenues and perspectives for patients and physicians. This expectation is further supported by newly published data on a potential antiviral efficacy of DSCG that may be particularly important in the treatment of pediatric asthma," added Dr. Manfred Keller, chief scientific officer and executive vice president of PARI Pharma.

At ATS, PARI Pharma also presented in-vitro data comparing IsoCrom (1%) with a novel, higher concentrated (6%), low volume DSCG formulation that requires significantly less nebulization time than IsoCrom. The results of this in-vitro study using 45mg/0.75ml may allow the option for twice-daily administration in less than 2.5 minutes.

IsoCrom & ICS Comparative Study Results

Data from a randomized, open-label, Phase II, six-month study comparing efficacy and safety of an IsoCrom solution versus inhaled steroids was presented by researchers from the pediatric department of the University Hospital Zurich, Switzerland. Twenty eight children (11.9 +/- 2.8 years) with stable atopic asthma were randomized to inhale either IsoCrom, delivered at a dose of 60 mg per day administered in three inhalations of 2ml using a customized small droplet Investigational eFlow Nebulizer System, or inhaled corticosteroids (ICS) without dose adjustments administered in two inhalations using a metered dose Inhaler (MDI) via a holding
'/>"/>

SOURCE PARI Pharma
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. ePharmaSolutions Clinical Trial Investigator Portal Wins Bio-IT World 2009 Best Practice Award
2. Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C
3. Pharmasset Voluntarily Halts Clinical Studies with Clevudine in Hepatitis B Infected Patients
4. Pharmasset Initiates First Time in Human Study of PSI-7851 for the Treatment of Hepatitis C (HCV)
5. Pharmasset Reports Fiscal Year End 2008 Financial Results
6. Roche, InterMune and Pharmasset Announce Initiation of INFORM-1, the First Dual-Combination Clinical Trial with Oral Antivirals in Hepatitis C
7. Richard E.T. Smith, Ph.D. Joins Pharmasset as Vice President of Investor Relations and Corporate Communications
8. Pharmasset to Present at the UBS Global Life Sciences Conference on Wednesday, September 24th
9. Pharmasset Reports Financial Results for Quarter Ended June 30, 2008
10. Pharmasset Reports Preliminary Results of a 4-week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
11. Pharmasset Announces Initiation of Combination Study of Clevudine and Viread(R) for HBV by French National Agency for Research on AIDS and Viral Hepatitis (ANRS)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... SAN DIEGO , July 1, 2015  AVACEN, Inc. ... a second AVACEN patent covering the medical technology platform supporting ... Logo - http://photos.prnewswire.com/prnh/20150630/227364LOGO ... The apparatus and methods patent no. 9,066,781 - Methods And ... devices manufactured by AVACEN and specific methods of use, referred ...
(Date:7/1/2015)... Fla. , July 1, 2015 Rock ... development company focused on chronic inflammatory disease and neurologic ... of principle study with anatabine citrate, the Company,s lead ... oral dose of anatabine citrate can significantly inhibit the ... subjects. The Company is developing this compound in a ...
(Date:7/1/2015)... , July 1, 2015 Egalet Corporation ... specialty pharmaceutical company focused on developing, manufacturing and ... Bob Radie , president and chief executive officer, ... summer. He will provide an update on Egalet,s ... tromethamine) Nasal Spray, approved product OXAYDO ™ ...
Breaking Medicine Technology:AVACEN Medical Patent Issued 2Rock Creek Pharmaceuticals Reports Human Proof of Principle Study of Lead Compound Demonstrating Inhibition of Inflammatory Markers In White Blood Cells 2Rock Creek Pharmaceuticals Reports Human Proof of Principle Study of Lead Compound Demonstrating Inhibition of Inflammatory Markers In White Blood Cells 3Rock Creek Pharmaceuticals Reports Human Proof of Principle Study of Lead Compound Demonstrating Inhibition of Inflammatory Markers In White Blood Cells 4Egalet to Present at Upcoming Conferences This Summer 2Egalet to Present at Upcoming Conferences This Summer 3
... -Study Results Show Cethromycin Not Associated with QT Prolongation- ... -Favorable Cardiac Safety Profile Strengthens NDA-, CHICAGO, ... ADLS ), today announced positive results from Trial,CL07-001, a ... cethromycin. This study was conducted to evaluate the cardiac,safety ...
... landscape of scientific,publications strategy, planning and delivery is ... global publications groups are fully,located in the marketing ... groups to increase clinical presentation, according to a ... a benchmarking study that included such influential companies ...
Cached Medicine Technology:Advanced Life Sciences Announces Successful Thorough QT Study of Cethromycin 2Advanced Life Sciences Announces Successful Thorough QT Study of Cethromycin 3Advanced Life Sciences Announces Successful Thorough QT Study of Cethromycin 4Advanced Life Sciences Announces Successful Thorough QT Study of Cethromycin 5Advanced Life Sciences Announces Successful Thorough QT Study of Cethromycin 6Industry Executives Finding Value in Shift of Scientific Publications 2
(Date:7/1/2015)... ... 01, 2015 , ... Sir Fazle Hasan Abed, BRAC’s founder and chairperson, was ... has been recognised for his outstanding contribution to enhancing the world's production and distribution ... the World Food Prize Foundation, announced this year’s winner at a ceremony at the ...
(Date:7/1/2015)... ... July 01, 2015 , ... The Lymphoma Research ... lymphoma research and serving the lymphoma community through a comprehensive series of education ... four new members to their industry leading Scientific Advisory Board. LRF’s volunteer Scientific ...
(Date:7/1/2015)... ... July 01, 2015 , ... DIC ... plant for Linablue®, Spirulina-derived natural blue food coloring. Construction of the plant, which ... U.S. Spirulina* production base, began in May 2014. After commissioning, commercial production is ...
(Date:7/1/2015)... Plainsboro, NJ (PRWEB) , ... July 01, 2015 ... ... Cannon , the global cancer enterprise of Hospital Corporation of America (HCA), as ... treatment and research, OncLive announced today. , With this new partnership, OncLive’s ...
(Date:7/1/2015)... ... 2015 , ... The 28th annual Charity Horse Show hosted by the Mid-South ... 6 p.m. in Pugh Bourne Park, 343 Oakfield Road. The event will again benefit ... Elvis impersonator, a silent auction and concessions. , Horses and riders from around the ...
Breaking Medicine News(10 mins):Health News:Sir Fazle Hasan Abed Receives World Food Prize 2Health News:Sir Fazle Hasan Abed Receives World Food Prize 3Health News:Lymphoma Research Foundation Welcomes New Scientific Advisory Board Members 2Health News:Lymphoma Research Foundation Welcomes New Scientific Advisory Board Members 3Health News:Lymphoma Research Foundation Welcomes New Scientific Advisory Board Members 4Health News:Lymphoma Research Foundation Welcomes New Scientific Advisory Board Members 5Health News:DIC Strengthens Its Position as the Global Leader for Natural Blue Food Coloring 2Health News:DIC Strengthens Its Position as the Global Leader for Natural Blue Food Coloring 3Health News:OncLive® Welcomes Sarah Cannon Cancer Network to Its Strategic Alliance Partnership Program 2Health News:OncLive® Welcomes Sarah Cannon Cancer Network to Its Strategic Alliance Partnership Program 3
... team has discovered a new protein family that may play ... some forms of cancer and even heart disease. , The ... system are published in the March 7 edition of the ... the National Institutes of Health. , What we found is ...
... MS Awareness Week March,10 - 17 unites MS organizations ... nationwide in an effort to shine a spotlight on ... disease where someone is,newly diagnosed each hour., (Logo: ... Ways To Join The MS Movement, The ...
... Hib meningitis has been virtually eliminated in,young children ... introduced Haemophilus influenzae type,b (Hib) vaccine nationwide, according ... b is a leading cause of pneumonia and ... and spinal cord. Each year, Hib kills approximately ...
... the charge in adapting drug dosing to a society ... of obesity in the Western World continues to rise ... researchers face the ongoing challenge of determining just how ... compositions. , In a pharmacological sense, obesity presents ...
... Carell, Stephen, Colbert, Susie Essman, Will Ferrell, Tina Fey, Jonah Hill, Kevin ... Triumph The Insult Comic Dog And Many More To Be ... And xBox Live, Marketplace For $1.99 For 30 Days After Airdate With All ... ...
... Patient Care and Reduced Costs for Hospitals by ... Service Delivery with Significant ROI, DETROIT, March ... launched a new initiative to provide hospitals and,physicians ... dynamically,changing healthcare technology environment. By proactively managing service,delivery ...
Cached Medicine News:Health News:UCF researchers discover a new protein family implicated in inflammatory diseases 2Health News:What Will You Do? Join the Movement to End Multiple Sclerosis During MS Awareness Week March 10-17 2Health News:What Will You Do? Join the Movement to End Multiple Sclerosis During MS Awareness Week March 10-17 3Health News:What Will You Do? Join the Movement to End Multiple Sclerosis During MS Awareness Week March 10-17 4Health News:Deadly disease eliminated in children under 5 years of age in Uganda 2Health News:Deadly disease eliminated in children under 5 years of age in Uganda 3Health News:Deadly disease eliminated in children under 5 years of age in Uganda 4Health News:COMEDY CENTRAL(R) Announces Live On-Air Charity Special 'Night Of Too Many Stars: An Overbooked Benefit For Autism Education' Hosted by Jon Stewart on Sunday April 13, at 8 p.m. ET 2Health News:COMEDY CENTRAL(R) Announces Live On-Air Charity Special 'Night Of Too Many Stars: An Overbooked Benefit For Autism Education' Hosted by Jon Stewart on Sunday April 13, at 8 p.m. ET 3Health News:Compuware Launches Strategic IT Service Management Initiative for Healthcare Industry 2Health News:Compuware Launches Strategic IT Service Management Initiative for Healthcare Industry 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: